Korea’s stock market has been removed from the MSCI Developed Markets Indexes’ watch list of candidates for inclusion in the index. The country’s hopes for inclusion in the indexes have been marking time for nine years.On June 11, MSCI classified South Korea as an emerging market as it released its
Recently, SK Telecom returned its 5G 28 GHz frequency license to the Korean government. This means that all three major Korean wireless carriers have given up the band. Earlier, they were fined a combined 33.6 billion won (US$25.7 million) by the Korea Fair Trade Commission (KFTC) for their overly e
SK bioscience announced on May 30 that its in-house developed COVID-19 vaccine “Sky Covione” (European name: Sky Covion) has received formal authorization from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for primary vaccination (first and second doses) in adults aged 18
Yuhan Corporation announced on May 30 that it has signed a technology licensing agreement with J INTS BIO for the tyrosine kinase inhibitor (TKI) “JIN-A04” targeting HER2.The total contract size amounts to 429.8 billion won (US$325.8 million), inclusive of an upfront payment of 25 billion won (US$19
On May 25, HanAll Biopharma and Daewoong Pharma announced a joint development agreement on potential treatments for degenerative neurological diseases. The agreement centers on ATH-399A, a leading candidate for Parkinson's disease treatment, currently under development at NurrOn Pharmaceuticals.
The author is an analyst for NH Investment & Securities. He can be reached at jaemin.ahn@nhqv.com -- Ed.Regulatory uncertainties abound in the telecom industry in 1H23. After KT’s failure to appoint a new CEO, government regulations for the telecom industry have strengthened, leading to the introduc
Hanall Biopharma announced on May 19 that it failed to achieve the statistical significance of the primary endpoint in a U.S. Phase 3 clinical trial (clinical name: VELOS-3) of HL036 (element name: Tanfanercept), a new drug for the treatment of dry eye disease.HL036 is a biologic drug jointly develo
The author is an analyst for NH Investment & Securities. He can be reached at seungyeon.han@nhqv.com -- Ed.We expect HanAll Biopharma to showcase a new royalty revenue business model within the Korea biotech industry. The firm is to generate large-scale global royalty revenue by developing next-gene
SK hynix's NAND Flash Solutions subsidiary, Solidigm, announced on May 16 that it had appointed Noh Jong-won, president of SK hynix, and David M. Dixon, vice president of Solidigm, as the new co-CEOs of Solidigm. The decision was made during a board meeting held in the U.S. on May 11, local time
The author is an analyst for NH Investment & Securities. He can be reached at jaemin.ahn@nhqv.com -- Ed.Weighed upon by market concerns toward absence of CEO, KT’s share price has now dropped more than 20% from its previous peak. But, related uncertainties should be eliminated gradually through BOD
SK bioscience announced on May 8 that it has signed a new production agreement for a next-generation Ebola vaccine candidate with global healthcare company MSD.The signing ceremony in Seoul was attended by government officials including Park Min-soo, vice minister of Health and Welfare; Sanat Chatto
Daewoong Pharmaceutical announced that it signed an agreement to license its autoimmune disease drug candidate DWP213388 to Vitalli Bio, a subsidiary of Aditum Bio, a U.S. biotech investment company, at the Korea-U.S. Digital and Bio-health Business Forum held in Boston, the United States, on April
President Yoon Suk-yeol, who is on a state visit to the United States, worked to convince Tesla CEO Elon Musk to build a factory in South Korea on April 26 (local time).The Korean government clarified its position that it will consider giving Tesla cash support of up to 50 percent of its investment
The National Policy Committee of the National Assembly passed a bill for virtual asset investor protection on April 25.According to the bill, the Bank of Korea can request information and data from virtual asset service providers. This is because such information and data may be necessary for moneta
On April 20, Dong-A ST announced the results of a preclinical study of its immuno-oncology drug candidate “DA-4505” at the American Association for Cancer Research (AACR) 2023 held in Orlando, Florida in the United States from April 14 to 19.At this meeting, Dong-A ST presented the anti-tumor effect
Shinhan Financial Group Chairman Jin Ok-dong has embarked on his first overseas investor relations (IR) trip since taking office to attract investment from Japanese institutional investors and serve as a bridgehead to promote private economic exchanges between Korea and Japan. The trip will last fro
LG Display is struggling looking for an exit strategy for its Chinese business amid a prolonged slump in the liquid crystal display (LCD) panel industry. The company is facing various scenarios including, sale to a Chinese company and a large-scale process transformation, as it urgently needs to imp
CJ Bioscience, an affiliate of CJ CheilJedang, announced on April 13 that it would present a poster of the results of preclinical trials on CJRB-101 at the American Association for Cancer Research (AACR) 2023, one of the world’s top three cancer societies. CJRB-101 is a new drug candidate (pipeline)
Taiwan’s TSMC has secured an advantageous position to preoccupy the EU market with the countdown to the passing of an EU version of America’s Chips Act to give chipmakers subsidies of about 60 trillion won.According to Taiwanese media outlets on April 10, a number of TSMC partner companies have rece
CJ CheilJedang’s CJ Bioscience announced on March 27 that it has signed an agreement to acquire promising drug candidates and platform technologies from 4D Pharma, a UK- and Ireland-based microbiome company.The newly introduced drug candidates total nine, targeting solid cancer, digestive diseases,